CANCER AND LEUKEMIA GROUP B

杜克医疗中心目前正在完成其第一个5年赠款周期 癌症和白血病组B（CALGB）的成员。 在此期间 在此期间，杜克大学一直是世界五大学府之一， 总体患者增加，并且一直是患者 主要成员机构的应计利润。 杜克目前正在开发一种 联盟计划，这将导致患者的大幅增加 权责发生制。 协调校内和校外的临床试验 通过杜克的中央礼宾办公室 该办公室提供核心 行政支持和质量保证为一大群 研究护士和数据管理员，他们协调临床试验， 疾病和模式的具体基础。 这种组织结构是 通过与CALGB生物统计学的密切互动得到进一步加强 和数据管理中心在杜克博士的指导下 乔治说，他也是杜克癌症中心的生物统计学主任。 作为科学家，杜克对所有疾病都有积极的骨干成员， 模式相关的CALGB委员会。 目前，杜克大学的12名调查人员 参与正在进行或计划进行的CALGB试验。 杜克大学的调查人员 担任即将进行的随机III期试验的研究主席， 年龄小于60岁的AML患者， 强化CHOPE化疗联合集落刺激因子支持 非霍奇金斯淋巴瘤，大剂量的主要国家随机试验 自体骨髓支持辅助化疗 治疗乳腺癌，紫杉醇在第三阶段乳腺癌的未决试验 癌症患者，一些呼吸道癌症和GU癌症试验。 在 此外，杜克一直是药理学I期试验的中心， 和实验疗法，并一直是一个领先的中心， 心理肿瘤学 多模态。还得到了下列方面的支持： 肿瘤外科、放射肿瘤科、 病理学及相关科学。 此外，杜克一直是一个主要的 少数患者增加和高优先级试验的贡献者。 地区 杜克大学的研究人员在下一次拨款中在CALGB内进行扩张 循环将涉及癌症控制，癌症治疗成本分析， 老年肿瘤学 作为CALGB活动的领导机构， 在最初的赠款周期，杜克期待着资金支持 适合我们当前和预期的患者累积水平， 在下一个资助周期，科学界参与CALGB试验。

Duke Medical Center is currently completing its first 5 year grant cycle as a member of Cancer and Leukemia Group B (CALGB). During this time period, Duke has consistently been one of the top five institutions in overall patient accrual, and has been the leading institution in patient accrual from a main member institution. Duke is currently developing an affiliate program which will lead to a substantial increase in patient accrual. Both intramural and extramural clinical trials are coordinated through a central protocol office at Duke. This office provides core administrative support and quality assurance for a large group of research nurses and data managers who coordinate clinical trials on a disease and modality specific basis. This organizational structure is further strengthened by close interaction with the CALGB biostatistics and data management center at Duke under the direction of Dr. Stephen George, who is also Director of Biostatistics for the Duke Cancer Center. Scientifically, Duke has active cadre members on all the disease and modality related CALGB committees. Currently, 12 investigators at Duke are involved in ongoing or planned CALGB trials. Duke investigators serve as study chairs on the pending randomized Phase III trial for patients with AML less than 60, the randomized Phase III trial of dose intensified CHOPE chemotherapy with colony stimulating factor support in non Hodgkins lymphoma, the major national randomized trial of high dose chemotherapy with autologous bone marrow support in the adjuvant treatment of breast cancer, the pending trial of Taxol in StageIII breast cancer patients, a number of respiratory cancer and GU cancer trials. In addition, Duke has been a center for Phase I trials for the pharmacology and experimental therapeutics and has been a leading center for psycho-oncology. Multi modality. support has also been provided by active participation from surgical oncology, radiation oncology, Pathology and correlative sciences. In addition, Duke has been a major contributor to minority patient accrual and high priority trials. Areas of expansion by Duke investigators within the CALGB over the next grant cycle will involve cancer control, cancer treatment cost analysis, and gero-oncology. As a leading institution in CALGB activities during our initial grant cycle, Duke is looking forward to funding support appropriate to our current and anticipated level of patient accrual and scientific involvement in CALGB trials during the next grant cycle.